Previous determinations of spontaneous variability in ventricular arrhythmia have often been based on measurements from consecutive days in small patient populations, whereas clinical determinations of drug efficacy typically compare measurements at intervals of 1 week and longer to baseline. We, therefore, sought to determine whether spontaneous arrhythmia variability changes as a function of time during periods ranging from 1 day to 1 year or longer. The percent reduction in the frequency of total premature ventricular complexes (PVCs) and repetitive ventricular beats required to show true drug effect rather than spontaneous variability in PVCs was determined in 47 consecutive patients with chronic ventricular arrhythmias who underwent multiple ambulatory monitor recordings while off active drug treatment (during placebo therapy). The variability in PVC rate was determined during the intervals of 1 day, 1 week, 2 weeks, 3 weeks, 4 weeks, and 1 year or longer. The percent reductions in total PVCs required to exceed the 95% confidence limits of spontaneous variability at these intervals were 55%, 85%, 86%, 93%, 96%, and 96%, respectively. Corresponding values for repetitive beats were 75%, 95%, 92%, 95%, 94%, and 98%, respectively. The percent increase in total PVCs and repetitive beats required to establish "arrhythmia aggravation" caused by an antiarrhythmic drug with a 95% confidence limit also was calculated for this study population and was 124% and 303%, respectively, at 1-day intervals and 2,269% and 4,091%, respectively, at l-year (or longer) intervals for the 24-hour monitor recordings. Variability was not substantially affected by underlying heart disease or ejection fraction. PVC rate showed a modest negative correlation with variability (r=0.3). Thus, variability is substantially greater at 1 week, the usual time for clinical assessment of antiarrhythmic drug efficacy, than at 1 day (p<0.01). Suppression of more than 85% of total PVCs and more than 95% of repetitive beats appears to be necessary after 1-2 weeks to be confident of a true drug effect. Even greater variability is observed after 1 month and up to 1 year so that reductions of up to 95% in total PVCs and 98% in repetitive beats may represent spontaneous change. True antiarrhythmic drug effects and also proarrhythmic effects may be better assessed by reducing the time (to .2-4 days) between drug-free (baseline) and drug-testing recordings and by reassessing efficacy during short drug-washout periods during the course of long-term treatment than by the common practice of comparing multiple consecutive baseline recordings with distant treatment recordings. (Circulation 1988;78:286-295) A mbulatory electrocardiographic recording is used widely for detecting arrhythmias and for guiding antiarrhythmic therapy since Holter' first suggested its potential value. The frequency of ventricular arrhythmia occurrence and its
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The third guideline is based on an assumption that has not been fully tested: that the extent of spontaneous variability in an individual patient can be obtained in 2-4 consecutive days. It is possible, however, that there is a longer-term spontaneous change in the frequency of arrhythmia occurrence in individual patients that may not be obtained in consecutive daily monitoring periods. Because initial testing of antiarrhythmic drug efficacy typically occurs at least 1-2 weeks after the baseline measurements are taken, primary interest should be focused on spontaneous variability taken during these and longer intervals rather than on spontaneous variability taken during a 1-4 day interval as has been done in most previous studies.
In the present study, we measure and describe the extent of spontaneous variability in both total premature ventricular complexes (PVCs) and repetitive beats between 24-hour ambulatory electrocardiographic recordings separated by widely different time intervals in patients with chronic, complex ventricular arrhythmias, and we examine the implication of the time-related variability observed for evaluating antiarrhythmic therapy.
Patients and Methods Patient Selection Criteria
Consecutive patients enrolled in the hospital's clinic for arrhythmia therapy studies and who underwent serial ambulatory electrocardiographic monitor evaluations while off of antiarrhythmic drugs were included in the analysis. Patients were referred for antiarrhythmic drug therapy for symptom or mortality risk reduction. Chronic, frequent PVCs averaging at least 30 PVCs/hr on 24-48 hour ambulatory electrocardiographic recordings were required for entry into the arrhythmia therapy clinic. Qualifying ventricular arrhythmias could occur as iso-tricular tachycardia of up to 10 beats in duration. Patients with sustained, symptomatic, or hemodynamically significant ventricular tachycardia or outof-hospital cardiac arrest were not included in the present study. Patients with recent (<3 months) myocardial infarction or cardiac surgery were also excluded. All antiarrhythmic drugs were discontinued at a median of 11 days before monitoring (minimum, five half-lives). A constant dose of digitalis was permitted if it was required for treatment of congestive heart failure but was rarely used (six patients). 83-Adrenergic receptor blockers were not permitted if they were used for antiarrhythmic therapy. (One patient was taking a constant dose of p-blocker for hypertension.)
Ambulatory Electrocardiographic Recording
Ambulatory electrocardiographic recordings were performed on simultaneous two-channel tape recorders (Spacelabs, Redmond, Washington) and were analyzed by an experienced, validated computerbased, operator interactive system (Cardio-Data Systems, Haddonfield, New Jersey). The technician analyzing the data was unaware of patient characteristics or study plan. Ventricular arrhythmias were quantified as hourly frequencies of total PVCs and repetitive beats. The extent of spontaneous variability between 24-hour ambulatory electrocardiographic recordings separated by different time intervals was the primary measurement of interest. Each 24-hour recording is, therefore, referred to as an individual observation. Patients often received antiarrhythmic medication between observation periods; however, this medication was withdrawn at a median of 11 days before monitored observations (minimum, five half-lives). Patients previously on amiodarone were excluded. Thus, observations were all made in the absence of detectable circulating levels of antiarrhythmic drugs or important metabolites. The number of days separating the paired observations ranged from 1 day (defined as 24-hour recordings taken on 2 consecutive days) to 1,154 days. We selected for analysis 1 day, 4-10 days ("1 week"), 11-17 days ("2 weeks"), 18-24 days ("3 weeks"), 25-31 days ("4 weeks"), and 365 days or longer (".;1 year") as the intervals of interest between observations. These were selected as representative times of interest for the usual clinical follow-up in these arrhythmia patients.
Many patients had multiple observations separated by a similar time interval (e.g., patient 3 had two paired observations separated by 4-10 days, one pair on days 2 and 8, and the second pair on days 378 and 385). However, only one of these paired observations for each patient was allowed in the analysis (Table 1 ). To ensure that no bias occurred in the selection of these observations, two rules were used to choose from among the multiple occurrences of a given interval in a particular patient. First, the interval between observations closest to lated beats, couplets, and runs of unsustained ven- For example, the midpoint of the 4-10-day interval is 7 days, and in patient 3, 6 days separated the observations on days 2 and 8, while 7 days separated the observations on days 378 and 385. Therefore, the observations on days 378 and 385 were chosen for analysis. Second, if the number of days between observations was equally close to the midpoint of the interval, the observations that occurred earlier were chosen.
Patient Entry Characteristics
Forty-seven patients were included in the analysis. There were 36 men and 11 women, and the average age was 60.0± 12.6 years (mean± SD; range, 34-81). Underlying heart disease included coronary artery disease in 26 patients, valvular heart disease in five, and cardiomyopathy and hypertension in one each. Fourteen patients had no detectable organic heart disease. Left ventricular ejection fraction averaged 0.50±0.13 (range, 0.25-0.72). The demographic data for individual patients is shown in Table 2 .
Statistical Analysis
The measure of spontaneous variability used for defining arrhythmia "suppression" was the lower bound of the 95% confidence interval in percent change. This measure was described by Morganroth et a115 and Pratt et al, 22 and it represents the percent suppression required to show a significant departure from spontaneous variability or the percent suppression required to show a true drug effect. This measure was obtained for both total PVCs per hour and repetitive ventricular beats per hour. The first step in constructing this measure is to obtain the natural logarithm of PVCs per hour, In(PVCs/h + 1). This transformation reduces variability among patients and potentially eliminates the skewness in the distribution of PVCs per hour associated with the large differences in PVCs per hour among patients. One is added to the PVC rate so that in the event of a "(zero" response rate, the logarithm is defined. The second step in the procedure is to expose the measurements of ln(PVCs/h + 1) to a one-way analysis of variance in which patients are treated as the grouping factor. This analysis of variance results in two measures of variability: variability among patients, and variability among days within patients, which is pooldd over all patients in the study. This second measure of variability, before pooling, can be used to define variance among days for individual patients and is constructed by the usual formula 1(x V.
Here, the number of observations is always two, and the number of degrees of freedom is one. The individual variance among days was used in several analyses, and the pooled variability among days within patients was used to construct a 95% confidence interval; the limits of this confidence interval are transformed to a percent change. 15 The difference between spontaneous variability from different inter-recording intervals was evaluated with the F test for the ratio of variance. To construct this test, the mean squares among days within subjects from the analysis of variance described above was obtained for each of the interrecording intervals. The larger of these mean squares was divided by the smaller of the mean squares. This ratio was distributed as an F statistic with degrees of freedom equal to those used in the two mean squares estimates. Results 
Baseline Arrhythmia Frequency
The arithmetic mean hourly total PVC and repetitive ventricular beat frequency for all 47 patients on baseline day 1 was 533 + 502 PVCs/hr (median, 376; range, 43.6-1,897) and 38.8 ± 64.3 PVCs/hr (median, 7.7; range, 0-290), respectively. All but three patients had repetitive beats in the baseline-day 1 recording. The distribution of mean total PVC frequencies in the patient population on baseline day 1 is shown in Figure 1 , and actual individual values are given in Table 2 . This distribution, based on a log2 scale, is approximately symmetrical and confirms the utility of logarithmic transformation in reducing skewness in the distribution of PVCs per hour. Percent Suppression ofArrhythmia Required to
Establish Drug Effect
The minimal percent suppression required to demonstrate a significant drug effect at a confidence level of 0.95 was determined for total PVCs and repetitive beats for six different time-separation intervals. The percent arrhythmia reduction required to establish the occurrence of a true drug effect, as opposed to spontaneous variability alone, is 55.3% for total PVCs and 75.2% for repetitive beats if only 1 day separates the two recordings. Progressive, further increases in percent reduction in arrhythmia frequency are required, however, as the lengths of the intervals separating recordings are increased to 1 week and longer (Table 3, Figure 2 ). For example, the percent reduction in total PVCs that is required to show drug efficacy after 1 week of the start of treatment is 85%, and after 1 year or more, the percent reduction is 96%.
An F test for the ratio of variance between 1-day and 1-week inter-recording intervals was significant at the p<0.01 level for both total PVCs Similar statistical analysis, using the upper bound of the 95% confidence interval of spontaneous variability, was applied to establish criteria for "arrhythmia aggravation" for total PVCs and repetitive beats during the same periods of observation. Thus, an increase to 124% of baseline in total PVCs and 303% in repetitive beats is necessary to establish arrhythmia aggravation when the two monitored periods are separated by 1 day (Table 4 ). A much higher percent increase in total PVCs and repetitive beats is required to support arrhythmia aggravation rather than spontaneous variability alone when the separation intervals are further from baseline. For example, at 1 week, these necessary increases rise to 583% and 1,730%, respectively, and at 1 year or more, these increases rise to 2,269% and 4,091%, respectively.
Effect of Monotonic Changes in Premature Ventricular Complex Rate on Measures of Spontaneous Variability
It would be possible to explain the large increases in spontaneous PVC variability associated with increases in the inter-recording time interval if the natural history of the arrhythmia resulted in a monotonic change in PVC rate during the study. PVCs, premature ventricular complexes.
*With 95% confidence limit. This second possibility would occur if, for example, the drug therapy or a physiological process that intervened between recordings progressively "cured" the patient's arrhythmia. Such a monotonic change would render the observations on spontaneous variability trivial. To evaluate this possibility, individual patients were examined for changes over time in PVCs per hour compared with day 1. In this analysis, the maximum and minimum PVCs per hour were identified for all days excluding day 1. Then, the percent increase or decrease from day 1 to the minimum or maximum was calculated.
If the percent change (increase) was to greater than 120% of baseline, the patient was classified as showing an increase in PVC rate. If the percent change (decrease) was more than -20% from baseline, the patient was classified as showing a decrease. Of the 47 patients studied, 14 showed both increases (to a maximum of 1,361% of baseline) and decreases (to a minimum of -92%), 11 showed only an increase (to a maximum of 404%), 19 showed only a decrease (to a minimum of -92%), and three patients showed no change. Of the 11 patients who showed only an increase, nine were observed for 14 days or less, restricting the possibility of bidirectional change. Similarly, of the 19 patients who showed only a decrease, 10 were observed for 14 days or *With 95% confidence limit. a a-l---------- less. These observations do not support monotonic change as a major factor in determining long-term variability in our population.
Contribution of Individual Patients to Spontaneous Variability
It would be of clinical and scientific interest if individual patients could be identified prospectively who contributed unusually large amounts of spontaneous variability to the overall analysis (outliers). Among our patient population, only one patient (patient 3) appeared among the top 10% for variability in each of the inter-recording intervals, suggesting that only rarely do individual patients make consistently large contributions to within-subject variability measures. Also, patients who had high PVC rates on one occasion were found to generally have high PVC rates on other occasions. Correlations for the mean and variance of In(PVC/h + 1) are shown in Table 5 . High correlations (0.8-1.0) were observed among PVC rates taken at different interrecording intervals except at 1 year, where they were lower (0.3-0.6). Lower correlations were observed among the majority of inter-recording intervals for PVC variability. Serial data on variability for individual patients are presented in Figure 3 for those tested for each interval between 1 day and 1 month. Only patient 3 shows a consistent and increasing variability.
Relative PVC rates of individual patients were thus consistent for inter-recording intervals up to at least 1 month. Variability was much less consistent. PVC variability was high at one inter-recording interval and low at another interval for many patients.
These results confirm the well-known observation that between-patient variability generally overshadows within-patient variability on day-to-day PVC monitoring, and these results support the contention that there may be systematic spontaneous changes in PVC rate with cycle lengths as short as 1 week.
Effect of Premature Ventricular Complex Rate on Spontaneous Variability
Whether spontaneous variability is affected by PVC rate was also evaluated in our study population. The high correlation in PVC rate between different inter-recording intervals allowed averaging of PVC rates over all inter-recording intervals and assignment of patients to separate groups of high and low PVC rates. The percent suppression required to show a drug effect was then determined separately for each inter-recording interval for cu ._3 patients with PVC rates at or above the median compared with those below (350 PVCs/hr) ( Table  6 ). The percent suppression required to show a drug effect was generally larger for patients with lower PVC rates. An F test of the ratio of variances showed a significantly lower required-percent suppression for patients with high rates for every inter-recording interval except 1 week and 1 year or longer.
A scatter plot of individual patient data for variance (variability) compared with arrhythmia frequency at various time intervals is presented in Figure 4 for total PVCs and Figure 5 for repetitive PVCs (those in couplets or salvos). Although a significant negative correlation (r = 0.3, p<0.01) was observed for total PVCs, the slope is shallow and overlap is broad. Repetitive PVC rates were not significantly related to overall variability. Both figures show a general tendency for variability to be higher with longer inter-recording intervals.
Effect of Arrhythmia Etiology on

Spontaneous Variability
Spontaneous variability may differ for patients based on the presence or absence of organic heart disease. Percent suppression required to show a drug effect was thus determined separately for patients with idiopathic arrhythmia (n-14) and for patients with arrhythmia associated with organic heart dis- 10 1. n cc cU 100. 10 1. . The required percent suppression to show drug effect for each inter-recording interval for these two groups is given in Table 6 . The curve for patients with organic disease is quite similar to that for all patients (Figure 2 ). The curve for idiopathic patients is similar but slightly more erratic, perhaps due to the smaller number of patients. Only the comparison between groups at the 2-week interrecording interval was significantly different.
Effect of Left Ventricular Function on
Spontaneous Variability
The analysis of percent suppression required to show a drug effect was performed separately and was compared for patients with an ejection fraction at or above the median (0.5) and for patients with an ejection fraction below the median. The required percent suppression to show drug effect for each inter-recording interval is given in Table 6 . Overall, patients with an ejection fraction greater than 0.5 tended to require somewhat greater suppression to show a drug effect. However, none of the F tests for the ratio of variances was significant for any interrecording interval.
To summarize, we attempted to identify factors contributing to spontaneous variability. Only iso- lated individual patients (outliers) could be identified who contributed greater than the expected degree of variability. Of PVC rate, presence of organic disease, and ejection fraction, only PVC rate could be related (modestly) to variability. None of these factors allowed us to prospectively identify outliers. Moreover, there was an increase in the percent suppression required to show a drug effect comparing 1-day with 1-week inter-recording intervals in each subgroup of patients evaluated.
Discussion
The assessment of antiarrhythmic efficacy requires objective criteria. Our study indicates that to determine true drug effect at a 95%'confidence limit when the baseline and the treatment 24-hour ambulatory recordings are performed on consecutive days, a 55% reduction in total PVCs is required. However, assessments of drug efficacy are usually made in the clinical setting at intervals of 1 week or longer. For these intervals, the percent arrhythmia reductions required to establish drug effect are substantially greater: 85%, 86%, 93%, and 96%, at about 1 week, 2 weeks, 3 weeks, and 4 weeks, respectively. To establish continuing drug effectiveness 1 year or more later, reductions of 96% or greater in total PVCs and almost complete (.98%) reductions in repetitive beats are needed.
Several studies have described the extent of spontaneous variability in PVC rate between two 24-hour recordings.1 157-24 However, the majority of these studies have focused on a single interrecording interval that ranged from 1 day'5 '19'22 to 14 days20 to year or longer. 23 Only one study presents multiple inter-recording intervals in a single set of patients.2' In this study, Toivonen21 used regression techniques to show that at a median inter-recording interval of 3 days (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , the percent suppression required to show drug effect was approximately 70%, and at 9 months (range, 6-12), the percent suppression was approximately 98%. This is in substantial agreement with our results. How-ever, our results also show that the majority (80%) of the difference in variability between 1 day and long-term inter-recording intervals occurs by 1 week.
Simply put, our observations, together with previous studies,15,17-24 suggest that it is difficult for the clinician to distinguish a true drug response from the large spontaneous changes in PVC rate observed at the times that monitor recordings are usually taken to assess drug efficacy. This problem is further compounded by our observation that variability is time-interval dependent, with even higher levels of spontaneous variability occurring with longer intervals between recordings.
Our results suggest that long-term spontaneous changes in PVC rates cannot be obtained in 2-4 consecutive days of baseline recordings. If longterm variability differs from variability in PVC rates on consecutive days, an attempt to reduce statistical variability in arrhythmia frequency by extending baseline observations to 2-4 consecutive daily recordings, as previously suggested,15,19,22 might be misguided. Figure 6 was constructed to illustrate this problem and shows a hypothetical case of long-term spontaneous changes in PVC rates. If 4 consecutive days were observed at the points shown (or for that matter, at any other set of 4 consecutive days), the variability during those days would be far less than observed during a longer interval. This possibility is especially disconcerting when one considers that the longer time intervals between baseline and drug testing commonly apply to situations in clinical practice.
In an attempt to capture the full extent of spontaneous arrhythmia variability, an alternative suggestion is that multiple baseline recordings should be taken with longer intervals between recordings. This suggestion is questionable for several reasons. First, it is often economically and practically prohibitive. Second, it may place the patient at some potential risk from his untreated arrhythmia during a prolonged baseline phase. Third, if the full extent of long-term arrhythmia variability were used to establish a criterion for efficacy, the criterion might need to be so conservative that a true drug effect for anything less than 100% suppression is questionable.
Our data suggest that a reasonable alternative would be to reduce the time between baseline 24-hour drug-free and initial drug-testing recordings for initial determination of efficacy. Because there may be progressive long-term changes in spontaneous arrhythmia frequency, even during drug treatment, comparing PVC rates later during long-term drug treatment to PVC rates at baseline, weeks, or months before, may also be misleading. Therefore, monitoring before and after short drug-washout periods should be performed during long-term therapy to evaluate continuing drug efficacy. It would then be possible to evaluate the difference between means of these drug-washout recordings to address overall drug efficacy. These recommendations also find support from a recent study by Pratt et al.23
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They observed significant spontaneous changes (significant reductions in one third of patients) in baseline arrhythmia frequency after 1 year based on three consecutive, 24-hour initial recordings and long-term recordings (mean, 17 months) on placebo.
It should be added that brief interruptions during follow-up also put the patient at risk. Although these brief interruptions appear appropriate for the patients with symptomatic or potentially malignant arrhythmias, discussed here, they may be more hazardous in patients with a history of malignant (sustained) arrhythmias. In-hospital observations might be appropriate if cessation of antiarrhythmic therapy is attempted in patients with malignant ventricular arrhythmias.
It has now been well established that antiarrhythmic drugs may also aggravate ventricular arrhythmias.25 Based on our PVC variability data, we calculated the degree of arrhythmia increase necessary to establish arrhythmia aggravation. Based on 1 day of monitoring at baseline and during drug therapy, an enormous but also time-dependent increase in total PVCs at the different intervals examined is needed to document arrhythmia aggravation at the 95% confidence level (Table 4 ). Pratt et a124 have also reported a huge increase (1,780%) in PVCs necessary to determine arrhythmia aggravation when two ambulatory 24-hour recordings are separated by an average of 8 days. This value is even higher than the 583% increase calculated to define aggravation at 1 week in the present study. However, our population consisted of stable patients with chronic, complex ventricular arrhythmias, while Pratt's study comprised patients who had suffered acute myocardial infarction within the previous 6-60 days.
It should be stressed that our study observations are limited to patients with unsustained ventricular arrhythmias. Those with a history of sustained ventricular tachycardia and fibrillation were excluded. Although these latter patients with more serious ventricular arrhythmias are of substantial interest because of their high risk of sudden death, they form only a small minority (<5%) of arrhythmia patients evaluated in the setting of general practice. Also, there is a growing consensus that electrophysiological study is a more broadly appli-cable26,27 and more predictive method for monitoring these more malignant arrhythmias. 27, 28 The extent to which the behavior of spontaneous (monitored) arrhythmias in patients with a history of sustained ventriclar arrhythmias is similar to that of symptomatic but more benign or potentially malignant ventricular arrhythmias, studied here, is uncertain. However, the observations in our study patients are of general interest because ambulatory monitoring remains the method of choice for evaluating therapy in the large populations of patients who receive antiarrhythmic therapy for relief of symptoms or for suppression of prognostically significant arrhythmias.
Because most observation periods occurred after previous antiarrhythmic therapy, the question of residual drug or metabolite effect on observed results may be raised. However, a long washout time was allowed (median, 11 days) before monitoring, and drugs possessing unusually slow elimination (i.e., amiodarone) or complex active metabolites (i.e., encainide) were not used.
In summary, our findings confirm the substantial spontaneous variability in frequency of ventricular arrhythmias suggested by other authors, but in addition, our findings demonstrate that this change (increase) in variability is a function of time between recordings. This new observation of greater PVC variability when ambulatory monitor recordings are separated by the greater time intervals typically encountered in clinical drug evaluations (i.e., .1 week) suggests that many consecutive baseline ambulatory recordings may be of less value in helping to determine true drug effects in clinical practice than pairs of closely spaced (2-4 days) 24-hour recordings (drug-free vs. drug-treatment) that may be repeated at several points during the long-term course of drug treatment. Brief interruption of antiarrhythmic therapy after long time intervals appears to be necessary to determine whether the arrhythmia persists and to judge whether the antiarrhythmic drug is further needed. These conclusions have an even greater application to the question of drug-related arrhythmia aggravation.
